Novo Nordisk A/S (FRA:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 182.01B -2.2% |
| Revenue (ttm) | 44.06B +5.6% |
| Net Income | 15.57B +4.8% |
| EPS | 3.50 +5.0% |
| Shares Out | n/a |
| PE Ratio | 11.69 |
| Forward PE | 15.27 |
| Dividend | 1.57 (3.99%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 12,604 |
| Open | 38.53 |
| Previous Close | 38.38 |
| Day's Range | 38.27 - 40.86 |
| 52-Week Range | 30.29 - 54.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook
Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook
European Stocks Subdued as HSBC and Novo Nordisk Lead Declines
European stocks traded steady near a record high as falls in HSBC Holdings Plc and Novo Nordisk A/S helped erase early gains.
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
The Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.
Novo Nordisk Wins Dutch Court Injunction Against Compounded Semaglutide Nasal Spray
(RTTNews) - Novo Nordisk A/S (NVO) said Wednesday it secured a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V., ordering the company to immediately st...
Novo Nordisk Stock (NVO) Recovers as Earnings Surprise to the Upside
The company beat Wall Street forecasts across the board.
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case
Danish drugmaker Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. from a district court in the Netherlands in a patent infringement...
Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals
Chief Executive Mike Doustdar's comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
Novo Nordisk Earnings Call Transcript: Q2 2026
Adjusted sales rose 7% in Q2 2026, led by strong GLP-1 and obesity franchise growth, despite U.S. pricing pressure and increased self-pay mix. The Wegovy pill saw rapid global uptake, and the pipeline advanced with key trial readouts and new launches. Guidance for 2026 was raised, but headwinds remain.
Novo Nordisk Quarterly report: Q2 2026
Novo Nordisk has published its Q2 2026 quarterly earnings report on August 5, 2026.
Novo Nordisk Slides: Q2 2026
Novo Nordisk has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Novo Nordisk (NVO) Raises Guidance Amid Mixed Market Reactions
Novo Nordisk (NVO) Raises Guidance Amid Mixed Market Reactions
Novo Nordisk CEO addresses investors' high Wegovy pill expectations
Novo Nordisk hikes its 2026 outlook, but investors focus more on quarterly sales of the Danish pharma giant's Wegovy weight loss pill, which came in slightly lower than expected. CEO Mike Doustdar add...
Novo Nordisk CEO addresses investors' high Wegovy pill expectations
Novo Nordisk hikes its 2026 outlook, but investors focus more on quarterly sales of the Danish pharma giant's Wegovy weight loss pill, which came in slightly lower than expected. CEO Mike Doustdar add...
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Novo Nordisk raised its full year outlook late Tuesday. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, while obesity drug sales were larg...
Novo CEO faces investor grilling after outlook hike soured by pipeline concerns
Novo Nordisk CEO Mike Doustdar faces investors and analysts on Wednesday under pressure to restore confidence in the drugmaker's longer-term growth prospects after an upgraded 2026 outlook failed to...
Novo Nordisk AS (NVO) Shares Fall 6.0% -- What GF Score of 75 Tells Investors
Novo Nordisk AS (NVO) Shares Fall 6.0% -- What GF Score of 75 Tells Investors
Portal Innovations CEO John Flavin: Novo Nordisk is undervalued
John Flavin, Portal Innovations, joins 'Fast Money' to talk what to expect from pharma earnings.
Novo Nordisk (NVO) Raises Sales Guidance Amid Strong Demand for Weight Loss Drug
Novo Nordisk (NVO) Raises Sales Guidance Amid Strong Demand for Weight Loss Drug
The Wegovy pill's ‘surprise miss' is one reason Novo Nordisk's stock is down
The Danish drugmaker also revealed an improved outlook for the year.
Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes
US-listed shares of Novo Nordisk fell more than 6% on Tuesday after the Danish drugmaker released its second-quarter financial results and updated its full-year outlook a day ahead of its scheduled ea...
Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb
U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.
Novo Nordisk Raises Earnings Guidance. The Stock Sinks.
The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.
Novo Nordisk reports earnings, lowers U.S. outlook
CNBC's Annika Kim Constantino reports on news regarding Novo Nordisk.
Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day Early
Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.
Novo Nordisk shares slide after guidance disappoints investors
U.S.-traded shares of Novo Nordisk dropped more than 5% after the Danish drugmaker released guidance that appeared to disappoint investors. Novo Nordisk hiked its outlook, citing the strength of its W...